Pomc Phenotype Annotations

Mammalian Phenotype Ontology Annotations
Query Results - Summary

Symbol
Name
ID

Pomc
pro-opiomelanocortin-alpha
MGI:97742

77 phenotypes from 8 alleles in 16 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Pomc^{em1(IMPC)Rbrc}/Pomc⁺ C57BL/6NJcl-Pomc^{em1(IMPC)Rbrc}/Rbrc	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	impaired glucose tolerance	J:211773
Pomc^{em1(IMPC)Rbrc}/Pomc^{em1(IMPC)Rbrc} C57BL/6NJcl-Pomc^{em1(IMPC)Rbrc}/Rbrc	preweaning lethality, incomplete penetrance	J:211773
Pomc^tm1.1Kgm/Pomc^tm1.1Kgm involves: C57BL/6J	decreased oxygen consumption	J:263640
	normal homeostasis/metabolism phenotype	J:263640
	increased body fat mass	J:263640
	increased body length	J:263640
	increased body weight	J:263640
	polyphagia	J:263640
Pomc^tm1Low/Pomc⁺ involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2	increased pituitary adenoma incidence	J:119240
Pomc^tm1Low/Pomc⁺ Tg(Pomc)#Low/0 involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster	increased pituitary adenoma incidence	J:119240
Pomc^tm1Low/Pomc^tm1Low B6.129S2-Pomc^tm1Low	abnormal alcohol consumption	J:49706
	abnormal behavior	J:122110
	abnormal neuron physiology	J:113139
	abnormal operant conditioning behavior	J:49706
	abnormal response/metabolism to endogenous compounds	J:115712
	normal adipose tissue phenotype	J:115712
	normal homeostasis/metabolism phenotype	J:115712
	hyperactivity elicited by ethanol administration	J:49706
	impaired conditioned place preference behavior	J:122110
	impaired glucose tolerance	J:115712
	increased alcohol consumption	J:49706
	increased body weight	J:113139, J:115712
	increased circulating insulin level	J:115712
	increased circulating leptin level	J:115712
	increased fat cell size	J:115712
	increased gonadal fat pad weight	J:115712
	increased inguinal fat pad weight	J:115712
	increased physiological sensitivity to xenobiotic	J:115712
	increased renal fat pad weight	J:115712
	increased retroperitoneal fat pad weight	J:115712
	increased systemic arterial systolic blood pressure	J:113139
	increased total body fat amount	J:115712
	increased urine adrenaline level	J:113139
	obese	J:115712
	polyphagia	J:115712
Pomc^tm1Low/Pomc^tm1Low B6.129S2-Pomc^tm1Low/J	normal behavior/neurological phenotype	J:84463
	increased aggression towards mice	J:84463
	increased body weight	J:84463
	increased circulating corticosterone level	J:84463
Pomc^tm1Low/Pomc^tm1Low involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6	obese	J:115712
Pomc^tm1Low/Pomc^tm1Low involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2	decreased adrenal gland zona fasciculata size	J:119240
	decreased adrenocorticotropin level	J:119240
	decreased circulating adrenocorticotropin level	J:119240
	decreased circulating corticosterone level	J:119240
	disorganized adrenal gland zona fasciculata	J:119240
	increased pituitary adenoma incidence	J:119240
	perinatal lethality, incomplete penetrance	J:119240
	small adrenal glands	J:119240
Pomc^tm1Low/Pomc^tm1Low involves: 129S2/SvPas * C57BL/6	decreased circulating adrenocorticotropin level	J:102955
	decreased circulating corticosterone level	J:102955
	increased circulating interleukin-6 level	J:102955
	increased interleukin-6 secretion	J:102955
	increased splenocyte proliferation	J:102955
	increased tumor necrosis factor secretion	J:102955
Pomc^tm1Low/Pomc^tm1Low involves: 129S2/SvPas * C57BL/6 * Swiss albino	obese	J:115712
Pomc^tm1Low/Pomc^tm1Low involves: 129S2/SvPas * C57BL/6N	abnormal behavioral response to addictive substance	J:47711
	abnormal touch/ nociception	J:47711
	increased body weight	J:47711
Pomc^tm1Low/Pomc^tm1Low Tg(Pomc)#Low/0 involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster	abnormal corticosterone level	J:119240
	decreased adrenocorticotropin level	J:119240
	decreased circulating adrenocorticotropin level	J:119240
	enlarged adrenal glands	J:119240
	increased adrenal gland zona fasciculata size	J:119240
	increased body weight	J:119240
	increased circulating adrenocorticotropin level	J:119240
	increased circulating corticosterone level	J:119240
	increased pituitary adenoma incidence	J:119240
	normal mortality/aging	J:119240
Pomc^tm1Low/Pomc^tm1Low Tg(Pomc)#Low/Tg(Pomc)#Low involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster	increased body weight	J:119240
	increased circulating corticosterone level	J:119240
Pomc^tm1Sora/Pomc⁺ involves: 129S2/SvHsd * 129S6/SvEvTac	decreased circulating corticosterone level	J:89244
	diluted coat color	J:89244
	increased susceptibility to diet-induced obesity	J:89244
	normal integument phenotype	J:89244
Pomc^tm1Sora/Pomc^tm1Sora involves: 129S2/SvHsd * 129S6/SvEvTac	decreased circulating corticosterone level	J:89244
	decreased circulating thyroxine level	J:89244
	decreased oxygen consumption	J:89244
	decreased response to leptin	J:89244
	diluted coat color	J:89244
	increased susceptibility to diet-induced obesity	J:89244
	obese	J:89244
	polyphagia	J:89244
Pomc^tm2.1Low/Pomc^tm2.1Low B6.129S4(FVB)-Pomc^tm2.1Low	normal behavior/neurological phenotype	J:194013
Pomc^tm2.1Low/Pomc^tm2.1Low B6.129S4(FVB)-Pomc^tm2.1Low	normal growth/size/body region phenotype	J:194013
Pomc^tm2Low/Pomc^tm2Low B6.129S4-Pomc^tm2Low	decreased compensatory feeding amount	J:194013
	decreased locomotor activity	J:194013
	decreased oxygen consumption	J:194013
	hepatic steatosis	J:194013
	increased circulating glucose level	J:194013
	increased circulating insulin level	J:194013
	increased circulating leptin level	J:194013
	increased gonadal fat pad weight	J:194013
	increased inguinal fat pad weight	J:194013
	increased lean body mass	J:194013
	increased liver weight	J:194013
	increased retroperitoneal fat pad weight	J:194013
	increased total body fat amount	J:194013
	insulin resistance	J:194013
	obese	J:194013
	polyphagia	J:194013
Pomc^tm2Low/Pomc^tm2Low Tg(CAG-cre/Esr1)5Amc/0 involves: 129S4/SvJae C57BL/6 * CBA	abnormal body weight	J:194013
	decreased compensatory feeding amount	J:194013
	decreased food intake	J:194013
	decreased locomotor activity	J:194013
	decreased oxygen consumption	J:194013
	hepatic steatosis	J:194013
	increased body length	J:194013
	increased body weight	J:194013
	increased circulating glucose level	J:194013
	increased circulating insulin level	J:194013
	increased circulating leptin level	J:194013
	increased gonadal fat pad weight	J:194013
	increased inguinal fat pad weight	J:194013
	increased lean body mass	J:194013
	increased liver weight	J:194013
	increased retroperitoneal fat pad weight	J:194013
	increased susceptibility to weight gain	J:194013
	increased total body fat amount	J:194013
	insulin resistance	J:194013
	polyphagia	J:194013
Pomc^tm2Ute/Pomc⁺ involves: 129S1/Sv * 129X1/SvJ	normal growth/size/body region phenotype	J:57503
Pomc^tm2Ute/Pomc⁺ involves: 129S1/Sv * 129X1/SvJ	increased circulating leptin level	J:57503
Pomc^tm2Ute/Pomc^tm2Ute involves: 129S1/Sv * 129X1/SvJ	absent adrenal gland	J:57503
	decreased circulating adrenaline level	J:57503
	decreased circulating adrenocorticotropin level	J:57503
	decreased circulating aldosterone level	J:57503
	decreased circulating corticosterone level	J:57503
	diluted coat color	J:57503
	increased body length	J:57503
	increased circulating leptin level	J:57503
	increased dopamine level	J:57503
	increased food intake	J:57503
	increased susceptibility to diet-induced obesity	J:57503
	obese	J:57503
	prenatal lethality, incomplete penetrance	J:57503
	yellow coat color	J:57503
Tg(Pomc)#Low/0 involves: C57BL/6 * DBA/2	normal endocrine/exocrine gland phenotype	J:119240
	normal growth/size/body region phenotype	J:119240
	normal homeostasis/metabolism phenotype	J:119240

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/12/2024 MGI 6.24